Authors: Edwards G PMID: 14975065 PMCID: PMC2147658 DOI: 10.1186/1475-2883-2-S1-S8 Abstract The macrocyclic lactone ivermectin (Mectizan(R)) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. In areas [...]

Safety and pharmacokinetics (PK) of the antiparasitic drug ivermectin, administered in higher and/or more frequent doses than currently approved for human use, were evaluated in a double-blind, placebo-controlled, dose escalation study.

To assess the effect of ivermectin on immune function (antibody production), male CD-1 mice were inoculated with an antigen the day after SC administration of ivermectin (0.2 mg/kg of body weight or 20 mg/kg). Responses were evaluated 5 days after inoculation of the antigen. Antibody production against sheep RBC, a T lymphocyte-, macrophage-dependent response, was enhanced by ivermectin treatment (P = 0.00049). In contrast, antibody production against dinitrophenyl-Ficoll, a T lymphocyte-independent, macrophage-dependent response, was not altered by ivermectin treatment. Results indicate that the immunostimulatory properties of ivermectin are associated with altered function of T lymphocytes, in particular, T-helper lymphocytes. The immunomodulating effects of ivermectin may provide an alternative approach for treatment of disease problems involving immunosuppression.

Dr. Paul Marik's latest Cancer Care guide introduces a framework for simultaneously disrupting five metabolic systems in the cancer cell using repurposed drugs and nutraceuticals.

Treatment resistance is one of the biggest unsolved problems in cancer care. Dr. Paul Marik’s latest guide explains why it happens and introduces a practical cycling strategy designed to prevent it.

What does it cost to do the right thing in healthcare? A former hospital CEO, a board-certified pathologist, and an ICU physician share what they've learned.

Dr. Joseph Varon tells Full Measure why he launched the Journal of Independent Medicine to counter Big Pharma's grip on medical publishing.

“Why is the Texas Medical Board still fighting a war they’ve already lost? And why are they punishing Dr. Bowden for doing exactly what good doctors are supposed to do, fighting for her patients.” — Dr. Joseph Varon

Dr. Joseph Varon and Matthew Halma reflect on the first year of the Journal of Independent Medicine: the most-downloaded papers, the growth of independent publishing, and what's ahead.

Tim didn’t expect that his dog would teach him something about cancer care. But that’s where it started.